Coherus Distances Itself From Biosimilar Interchangeability
US Humira Biosimilars May Feature Designation In 2023
Coherus BioSciences has had its say on the prospect of interchangeability for Humira biosimilars, shortly after Boehringer Ingelheim announced positive data from a ‘first-of-its-kind’ switching study.
You may also be interested in...
Alvotech underlined that it could “save US consumers and taxpayers billions annually,” after hitting a key landmark in its Phase III switching study for its high concentration 100mg/ml biosimilar Humira product.
Acknowledging that “different companies have different views and approaches about interchangeability,” Samsung Bioepis has once again called into question the controversial designation.
Amid continued debate over biosimilar interchangeability in the US, Viatris has said it expects to pick up the first such approvals later this year with the company’s insulin glargine and insulin aspart biosimilar products.